Impaired Fibrinolysis in Obstructive Jaundice - Evidence from Clinical and Experimental Studies

Summary

Microvascular thrombosis is considered an important pathogenetic factor in renal failure associated with obstructive jaundice but the mechanisms leading to fibrin deposition are still unknown. The plasma levels of plasminogen activator inhibitor (PAI) in 29 patients with obstructive jaundice were found significantly increased as compared to 20 nonjaundiced patients. Fibrin autography of plasma supplemented with tissue plasminogen activator (t-PA) revealed that in icteric samples most of the added activator migrated with an apparent M_r of 100 kDa, corresponding to t-PA-PAI complex, whereas in control samples virtually all t-PA migrated as free enzyme. PAI activity detected in icteric samples is similar to the endothelial type PAI since it is neutralized by a monoclonal antibody against PAI-1.

Venous stasis in jaundiced patients was neither associated with an increase in blood fibrinolytic activity nor with a decrease in PAI activity. Immunologic assay showed that t-PA release was impaired in 3 out of 4 patients. In controls, venous occlusion induced an increase in both fibrinolytic activity and t-PA antigen and a reduction in PAI activity. Bile duct recanalization in jaundiced patients subjected to surgery was accompanied by a decrease in plasma PAI activity which paralleled the decrease in serum bilirubin levels. In nonjaundiced patients, surgical treatment did not cause significant changes in either parameter. Rabbits made icteric by bile duct ligation showed an early and progressive increase in plasma PAI activity indicating that obstructive jaundice itself causes the elevation of circulating PAI. It is concluded that obstructive jaundice is associated with a severe impairment of fibrinolysis which might contribute to microvascular thrombosis and renal failure.

Key words

PAI - t-PA - Obstructive jaundice - Thrombosis

• References

• 1 Pain JA, Cahill CJ, Bailey ME. Perioperative complications in obstructive jaundice: therapeutic considerations. Br J Surg 1985; 72: 942-945
• 2 Hunt DR, Allison ME M, Prentice CR M, Blumgart LH. Endotoxemia, disturbance of coagulation, and obstructive jaundice. Am J Surg 1982; 144: 325-329
• 3 Allison ME M, Prentice CR M, Kennedy AC, Blumgart LH. Renal function and other factors in obstructive jaundice. Br J Surg 1979; 66: 392-397
• 4 Wardle EN. Fibrinogen in liver disease. Arch Surg 1974; 109: 741-744
• 5 Takeda S, Takaki A, Ohsato K. Occurrence of disseminated intravascular coagulation (DIC) in obstructive jaundice and its relation to biliary tract infection. Jpn J Surg 1977; 7: 82-89
• 6 Sagar S, Shields R. Fibrinogen in the “hepato-renal syndrome”. Br J Surg 1980; 67: 562-564
• 7 Rodzynek JJ, Urbain D, Leautaud P, Wettendorff P, Delcourt A. Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance Gut 1984; 25: 1050-1056
• 8 Nillsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
• 9 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
• 10 Astrup T, Mullertz S. Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
• 11 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 12 Loskutoff DJ, Mussoni L. Interaction between fibrin and the plasminogen activators produced by cultured endothelial cells. Blood 1983; 62: 62-68
• 13 De Jong E, Knot EA R, Piket D, Iburg AH C, Rijken DC, Veenhof KH N, Dooijewaard J, ten Cate JW. Increased plasminogen activator inhibition levels in malignancy. Thromb Haemostas 1987; 57: 140-143
• 14 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 15 Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang JY, Kristensen P, Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells. Inhibitor neutralization and one-step affinity purification Thromb Haemostas 1986; 55: 206-212
• 16 Brommer EJ P, Verheijen JH, Chang GT G, Rijken DC. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemostas 1984; 52: 154-156
• 17 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 18 Paramo JA, De Boer A, Colucci M, Jonker JJ C, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis. Thromb Haemostas 1985; 54: 725
• 19 Paramo JA, Colucci M, van De Werf F, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
• 20 Hamsten A, Wiman D, De Faire U, Blombäck M. Increased levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 21 Krishnamurti C, Bar CF, Hasset MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
• 22 Colucci M, Paramo JA, Stassen JM, Collen D. Influence of the fast acting inhibitor of plasminogen activator (PA-inhibitor) on in vivo thrombolysis induced by tissue-type plasminogen activator (t-PA). J Clin Invest 1986; 78: 138-144